menu
    • menu

    Company profile for Invizius

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland, developing solutions to improve the treatment and prognosis for dialysis patients.Our proprietary H-Guard™ coating is a potent anti-inflammatory and anti-coagulant, which cloaks surfaces from the human immune system. Our team combines world-leading scientists with experienced life science executives and entrepreneurs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Inviziusunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    W Mains Rd, Edinburgh EH9 3LA.
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.invizius.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/invizius-limited
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/inviziusmed?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aptamer Teams Up with Invizius for Advanced Complement System
    Aptamer Teams Up with Invizius for Advanced Complement System

    03 Sep 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/aptamer-group-partners-with-invizius-to-develop-next-gen-complement-system-therapies/

    CONTRACTPHARMA
    03 Sep 2025
    Share Share
    Invizius completes first-in-human ‘angry blood’ dialysis study
    Invizius completes first-in-human ‘angry blood’ dialysis study

    13 Jun 2024

    // Conor Hale FIERCE BIOTECH

    https://www.fiercebiotech.com/medtech/invizius-completes-first-human-dialysis-trial-quell-angry-blood

    Conor Hale FIERCE BIOTECH
    13 Jun 2024
    Share Share
    Invizius’s Pioneering Dialysis Product H-Guard® Completes First In-Human Study
    Invizius’s Pioneering Dialysis Product H-Guard® Completes First In-Human Study

    22 May 2024

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2024-05-22/invizius-s-pioneering-dialysis-product-h-guard-completes-first-in-human-clinical-study

    PHARMIWEB
    22 May 2024
    Share Share
    Invizius Treats First Patients in Phase 1 Study of Lead Dialysis Product H-Guard
    Invizius Treats First Patients in Phase 1 Study of Lead Dialysis Product H-Guard

    07 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invizius-treats-first-patients-in-first-in-human-phase-1-clinical-study-of-lead-dialysis-product-h-guard-302054997.html

    PR NEWSWIRE
    07 Feb 2024
    Share Share
    Invizius Receives MHRA Approval to Commence Study of H-Guard® Priming Solution
    Invizius Receives MHRA Approval to Commence Study of H-Guard® Priming Solution

    01 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/invizius-receives-mhra-approval-to-commence-first-in-human-clinical-study-of-h-guard-priming-solution-301889906.html

    PR NEWSWIRE
    01 Aug 2023
    Share Share
    Invizius Awarded Major Biomedical Catalyst Grant
    Invizius Awarded Major Biomedical Catalyst Grant

    30 Mar 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/invizius-awarded-major-biomedical-catalyst-grant-to-bring-anti-inflammatory-haemodialysis-treatment-to-the-clinic-301513061.html

    PRNEWSWIRE
    30 Mar 2022
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search